MyMD Pharmaceuticals (MYMD) News Today → Guard Against the Coming Financial Upheaval (From Porter & Company) (Ad) Free MYMD Stock Alerts $2.53 +0.03 (+1.20%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative April 30, 2024 | msn.comGold prices fall as rate jitters mount ahead of Fed meetingApril 18, 2024 | msn.comMorning Bid: Dollar bulls enter the China shopApril 9, 2024 | investorplace.comWhy Is MyMD Pharmaceuticals (MYMD) Stock Up 35% Today?April 7, 2024 | uk.investing.comRecursion Pharmaceuticals CEO sells over $1.16m in stockMarch 28, 2024 | msn.comExclusive-Software industry calls for more UK Government supportMarch 5, 2024 | finance.yahoo.comMyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingFebruary 22, 2024 | benzinga.comMyMD Pharmaceuticals Stock (NASDAQ:MYMD), Short Interest ReportFebruary 15, 2024 | marketbeat.comTrading was temporarily halted for "MYMD" at 07:02 PM with a stated reason of "News pending."February 13, 2024 | msn.comMyMD Pharmaceuticals down after announcing reverse stock splitDecember 8, 2023 | morningstar.comMyMD Pharmaceuticals Inc Ordinary SharesDecember 7, 2023 | msn.comMyMD to begin Phase II trial of rheumatoid arthritis therapyOctober 20, 2023 | benzinga.comFive Hours Of Pain Relief? Preclinical Study Shows Promising Results With This Non-Toxic CBDOctober 19, 2023 | finance.yahoo.comMyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory PainOctober 18, 2023 | bizjournals.comBaltimore pharmaceutical company faces delisting from the NasdaqAugust 14, 2023 | finance.yahoo.comFDA Accepts MyMD Pharmaceuticals’ Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)July 31, 2023 | marketwatch.comMyMD Shares Surge on Positive Sarcopenia Study Results >MYMDJuly 31, 2023 | finance.yahoo.comMyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related FrailtyJuly 31, 2023 | marketbeat.comTrading was temporarily halted for "MYMD" at 08:07 AM with a stated reason of "News pending."May 17, 2023 | finance.yahoo.comWill MyMD Pharmaceuticals (NASDAQ:MYMD) Spend Its Cash Wisely?March 22, 2023 | benzinga.comMyMD Pharmaceuticals And Charles River Present Data For Next Generation, Oral TNF-α Inhibitor MYMD-1 In Rheumatoid ArthritisMarch 20, 2023 | finance.yahoo.comMyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid ArthritisMarch 8, 2023 | msn.comMyMD Joins LOT Network To Protect Company And Shareholders From Patent TrollsMarch 2, 2023 | finance.yahoo.comMyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed ChemicalFebruary 28, 2023 | finance.yahoo.comMyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual MeetingFebruary 21, 2023 | finance.yahoo.comMyMD Announces $15 Million Offering with Existing InvestorsDecember 6, 2022 | finance.yahoo.comADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022November 14, 2022 | finance.yahoo.comMyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug ResearchSeptember 22, 2022 | reuters.comHealthcare & PharmaceuticalsSeptember 20, 2022 | finance.yahoo.comMyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy LifespanAugust 31, 2022 | stockhouse.comMyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD(TM) CompoundAugust 30, 2022 | marketbeat.comShort Interest in MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) Grows By 24.8%MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD - Get Rating) was the target of a significant growth in short interest in the month of August. As of August 15th, there was short interest totalling 699,200 shares, a growth of 24.8% from the July 31st total of 560,200 shares. Approximately 2.0% of the company's shares are short sold. Based on an average daily trading volume, of 255,500 shares, the short-interest ratio is presently 2.7 days.August 30, 2022 | finance.yahoo.comMyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD™ CompoundAugust 29, 2022 | finance.yahoo.comMyMD Pharmaceuticals, Inc. (MYMD)August 5, 2022 | benzinga.comData Showing MyMD Pharmaceuticals' MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological SciencesJuly 29, 2022 | finance.yahoo.comIs MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) Popular Amongst Insiders?July 26, 2022 | finance.yahoo.comNew Therapeutics Options in Rheumatoid Arthritis Pipeline as 120+ Key Companies are Working on Drug Profiles | DelveInsightJuly 26, 2022 | finance.yahoo.comMyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy LifespanJuly 12, 2022 | finance.yahoo.comMyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic ConditionsJuly 7, 2022 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating MyMD Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsJune 18, 2022 | morningstar.comMyMD Pharmaceuticals Inc Ordinary Shares - Stock ChartApril 5, 2022 | finance.yahoo.comMyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy LifespanFebruary 23, 2022 | finance.yahoo.comMyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy LifespanJanuary 5, 2022 | seekingalpha.comMyMD Pharma secures new U.S. patent covering MYMD-1 in a method of treating sarcopeniaJanuary 5, 2022 | finance.yahoo.comMyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating SarcopeniaDecember 29, 2021 | finance.yahoo.comMyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast AsiaDecember 8, 2021 | benzinga.comFrom Benzinga's Global Small Cap Conference: MyMD Pharmaceuticals, Chief Scientific Officer, Adam Kaplin PH.D. Begins PresentingNovember 23, 2021 | finance.yahoo.comMyMD Pharmaceuticals Announces Issuance of U.S. Patent Covering Lead Drug Candidate MYMD-1 in a Method of Extending LifespanNovember 18, 2021 | finance.yahoo.comMyMD Pharmaceuticals Investment Company Oravax Medical and Genomma Lab Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin AmericaNovember 16, 2021 | finance.yahoo.comMyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy LifespanNovember 15, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating MyMD Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors Get MyMD Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MYMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Crypto Millionaire Says: “Buy This $11 AI Coin.” (Ad)Right now, you can harness the power of two bull markets... Artificial intelligence...And cryptos. Find out more about this $11 AI Coin right now MYMD Media Mentions By Week MYMD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MYMD News Sentiment▼1.440.57▲Average Medical News Sentiment MYMD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MYMD Articles This Week▼20▲MYMD Articles Average Week Get MyMD Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MYMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: NAVB News BMRA News TRIB News CDIO News OCX News XBIO News HOTH News HCTI News AVGR News KTRA News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MYMD) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersGuard Against the Coming Financial UpheavalPorter & CompanyClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsElon’s New Device is About to Shock the WorldInvestorPlaceCharles Payne Demystifies OptionsUnstoppable ProsperityNot Trump. Not Biden. But ___________.The Freeport SocietyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MyMD Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
